Atovaquone to be marketed as oral therapy for Pneumocystis carinii pneumonia.
D000284:Administration, Oral; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D053626:Atovaquone; D006801:Humans; D009285:Naphthoquinones / Q000008:administration & dosage / Q000627:therapeutic use*; D011020:Pneumonia, Pneumocystis / Q000188:drug therapy*
D000935:Antifungal Agents; D009285:Naphthoquinones; D053626:Atovaquone